Literature DB >> 33479413

Alpha-Klotho is a novel predictor of treatment responsiveness in patients with heart failure.

Manabu Taneike1,2, Makoto Nishida1,2, Kaori Nakanishi1, Fusako Sera2, Hidetaka Kioka2, Ryohei Yamamoto1, Tomohito Ohtani2, Shungo Hikoso2, Toshiki Moriyama1, Yasushi Sakata2, Keiko Yamauchi-Takihara3,4.   

Abstract

Heart failure is a major cause of death with an increasing population of elderly individuals. Several studies have demonstrated the involvement of soluble alpha-Klotho (sαKl) in various diseases. However, the correlation between sαKl and heart failure remains to be understood. The aim of this study is to investigate the levels and role of sαKl in patients with heart failure. Twenty-eight consecutive patients with acute heart failure (19 male, 9 female), admitted to the Osaka University Hospital from 2010 to 2018, were enrolled in this study. Mean NYHA score, left ventricular ejection fraction and BNP were 3.3, 17.0% and 588 pg/mL, respectively. SαKl significantly increased in heart failure patients. SαKl on admission were significantly higher in patients with heart failure who showed improvement after intensive treatment than that in patients who did not show improvement after the treatment. SαKl levels decreased significantly in patients who showed improvement. Interestingly, sαKl levels increased in male patients with heart failure, but not in female patients. Our data suggest that soluble αKl may be a novel biomarker for the responsiveness against treatment in patients with heart failure with reduced ejection fraction. Our findings may help developing a personalized therapy for different patients with heart failure.

Entities:  

Year:  2021        PMID: 33479413      PMCID: PMC7820312          DOI: 10.1038/s41598-021-81517-9

Source DB:  PubMed          Journal:  Sci Rep        ISSN: 2045-2322            Impact factor:   4.379


  27 in total

1.  Plasma klotho and cardiovascular disease in adults.

Authors:  Richard D Semba; Anne R Cappola; Kai Sun; Stefania Bandinelli; Mansi Dalal; Candace Crasto; Jack M Guralnik; Luigi Ferrucci
Journal:  J Am Geriatr Soc       Date:  2011-08-24       Impact factor: 5.562

Review 2.  Implications of Klotho in vascular health and disease.

Authors:  Ernesto Martín-Núñez; Javier Donate-Correa; Mercedes Muros-de-Fuentes; Carmen Mora-Fernández; Juan F Navarro-González
Journal:  World J Cardiol       Date:  2014-12-26

3.  An implication of Klotho-related molecules in different smoking-related health outcomes between men and women.

Authors:  Kaori Nakanishi; Makoto Nishida; Ryohei Yamamoto; Masahiro Koseki; Toshiki Moriyama; Keiko Yamauchi-Takihara
Journal:  Clin Chim Acta       Date:  2017-11-10       Impact factor: 3.786

4.  Mutation of the mouse klotho gene leads to a syndrome resembling ageing.

Authors:  M Kuro-o; Y Matsumura; H Aizawa; H Kawaguchi; T Suga; T Utsugi; Y Ohyama; M Kurabayashi; T Kaname; E Kume; H Iwasaki; A Iida; T Shiraki-Iida; S Nishikawa; R Nagai; Y I Nabeshima
Journal:  Nature       Date:  1997-11-06       Impact factor: 49.962

5.  High levels of plasma brain natriuretic peptide and interleukin-6 after optimized treatment for heart failure are independent risk factors for morbidity and mortality in patients with congestive heart failure.

Authors:  K Maeda; T Tsutamoto; A Wada; N Mabuchi; M Hayashi; T Tsutsui; M Ohnishi; M Sawaki; M Fujii; T Matsumoto; M Kinoshita
Journal:  J Am Coll Cardiol       Date:  2000-11-01       Impact factor: 24.094

6.  Serum klotho protein levels and their correlations with the progression of type 2 diabetes mellitus.

Authors:  Fang Nie; Dongming Wu; Hongfei Du; Xianggui Yang; Min Yang; Xueli Pang; Ying Xu
Journal:  J Diabetes Complications       Date:  2016-11-12       Impact factor: 2.852

7.  Circulating interleukin-6 family cytokines and their receptors in patients with congestive heart failure.

Authors:  Hisao Hirota; Masahiro Izumi; Tomoyuki Hamaguchi; Shoko Sugiyama; Eiki Murakami; Keita Kunisada; Yasushi Fujio; Yuichi Oshima; Yoshikazu Nakaoka; Keiko Yamauchi-Takihara
Journal:  Heart Vessels       Date:  2004-09       Impact factor: 2.037

8.  Targeted anticytokine therapy in patients with chronic heart failure: results of the Randomized Etanercept Worldwide Evaluation (RENEWAL).

Authors:  Douglas L Mann; John J V McMurray; Milton Packer; Karl Swedberg; Jeffrey S Borer; Wilson S Colucci; Jacques Djian; Helmut Drexler; Arthur Feldman; Lars Kober; Henry Krum; Peter Liu; Markku Nieminen; Luigi Tavazzi; Dirk Jan van Veldhuisen; Anders Waldenstrom; Marshelle Warren; Arne Westheim; Faiez Zannad; Thomas Fleming
Journal:  Circulation       Date:  2004-03-15       Impact factor: 29.690

9.  Protective Effect of Klotho against Ischemic Brain Injury Is Associated with Inhibition of RIG-I/NF-κB Signaling.

Authors:  Hong-Jing Zhou; Hui Li; Meng-Qi Shi; Xiao-Na Mao; Dong-Ling Liu; Yi-Ran Chang; Yu-Miao Gan; Xi Kuang; Jun-Rong Du
Journal:  Front Pharmacol       Date:  2018-01-18       Impact factor: 5.810

10.  Nomenclature for kidney function and disease: executive summary and glossary from a Kidney Disease: Improving Global Outcomes (KDIGO) consensus conference.

Authors:  Andrew S Levey; Kai-Uwe Eckardt; Nijsje M Dorman; Stacy L Christiansen; Michael Cheung; Michel Jadoul; Wolfgang C Winkelmayer
Journal:  Clin Exp Nephrol       Date:  2020-08-19       Impact factor: 2.801

View more
  3 in total

1.  Association between serum cotinine and α-Klotho levels among adults: Findings from the National Health and Nutrition Examination Survey 2007-2016.

Authors:  Yu Yao; Ying Long; Fa-Wang Du; Yong Zhao; Xiao-Bin Luo
Journal:  Tob Induc Dis       Date:  2022-06-14       Impact factor: 5.163

2.  Circulating α-Klotho Levels in Relation to Cardiovascular Diseases: A Mendelian Randomization Study.

Authors:  Xingang Sun; Lu Chen; Yuxian He; Liangrong Zheng
Journal:  Front Endocrinol (Lausanne)       Date:  2022-02-07       Impact factor: 5.555

3.  Development and Validation of a Nomogram Model for Predicting the Risk of Readmission in Patients with Heart Failure with Reduced Ejection Fraction within 1 Year.

Authors:  Yue Hu; Xiaotong Wang; Shengjue Xiao; Chunyan Huan; Huimin Wu; Tao Xu; Minjia Guo; Hong Zhu; Defeng Pan
Journal:  Cardiovasc Ther       Date:  2022-09-16       Impact factor: 3.368

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.